ALSFRS-R score and its ratio: A useful predictor for ALS-progression

Journal of the Neurological Sciences

Volumn 275, Issue 1-2, 2008, Pages 69-73

  Kollewe, Katja ^a   Mauss, Ulrike ^a   Krampfl, Klaus ^a   Petri, Susanne ^a   Dengler, Reinhard ^a   Mohammadi, Bahram ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

ALS; Disease progression; Predictors; Survival

Indexed keywords

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SCORING SYSTEM; SURVIVAL TIME;

ADULT; AGE FACTORS; AGE OF ONSET; AGED; AGED, 80 AND OVER; AMYOTROPHIC LATERAL SCLEROSIS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX;

EID: 55749095191     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2008.07.016     Document Type: Article

References (36)

1. Czaplinski A., Yen A.A., Simpson E.P., and Appel S.H. Predictability of disease progression in amyotrophic lateral sclerosis. Muscle Nerve 34(6) (Dec 2006) 702-708
2. Louwerse E.S., Visser C.E., Bossuyt P.M., and Weverling G.J. Amyotrophic lateral sclerosis: mortality risk during the course of the disease and prognostic factors. The Netherlands ALS Consortium. J Neurol Sci 152 Suppl 1 (Oct 1997) S10-S17
3. Chio A., Mora G., Leone M., Mazzini L., Cocito D., Giordana M.T., et al. Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology 59 1 (Jul 9 2002) 99-103
4. Cudkowicz M.E., Shefner J.M., Schoenfeld D.A., Brown Jr. R.H., Johnson H., Qureshi M., et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 61 4 (Aug 26 2003) 456-464
5. del Aguila M.A., Longstreth Jr. W.T., McGuire V., Koepsell T.D., and van Belle G. Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology 60 5 (Mar 11 2003) 813-819
6. Haverkamp L.J., Appel V., and Appel S.H. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 118 Pt 3 (Jun 1995) 707-719
7. Kaufmann P., Levy G., Thompson J.L., Delbene M.L., Battista V., Gordon P.H., et al. The ALSFRSr predicts survival time in an ALS clinic population. Neurology 64 1 (Jan 11 2005) 38-43.
8. Lacomblez L., Bensimon G., Leigh P.N., Guillet P., and Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 347 9013 (May 25 1996) 1425-1431
9. Magnus T., Beck M., Giess R., Puls I., Naumann M., and Toyka K.V. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve 25 5 (May 2002) 709-714
10. Stambler N., Charatan M., and Cedarbaum J.M. Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group. Neurology 50 1 (Jan 1998) 66-72
11. Caroscio J.T., Mulvihill M.N., and Sterling R. Abrams B. Amyotrophic lateral sclerosis. Its natural history. Neurologic clinics 5 1 (Feb 1987) 1-8
12. Kimura F., Fujimura C., Ishida S., Nakajima H., Furutama D., Uehara H., et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 66 2 (Jan 24 2006) 265-267
13. A controlled trial of recombinant methionyl human BDNF in ALS: the BDNF Study Group (Phase III). Neurology 52 7 (Apr 22 1999) 1427-1433
14. Groeneveld G.J., Veldink J.H., van der Tweel I., Kalmijn S., Beijer C., de Visser M., et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 53 4 (Apr 2003) 437-445
15. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group. Neurology 46 5 (May 1996) 1244-1249
16. Miller R.G., Moore II D.H., Gelinas D.F., Dronsky V., Mendoza M., Barohn R.J., et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 56 7 (Apr 10 2001) 843-848
17. Appel V., Stewart S.S., Smith G., and Appel S.H. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol 22 3 (Sep 1987) 328-333
18. Czaplinski A., Yen A.A., and Appel S.H. Amyotrophic lateral sclerosis: early predictors of prolonged survival. J Neurol 253 11 (Nov 2006) 1428-1436
19. Brooks B.R., Miller R.G., Swash M., and Munsat T.L. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Mot Neuron Disord 1 5 (Dec 2000) 293-299
20. Cedarbaum J.M., Stambler N., Malta E., Fuller C., Hilt D., Thurmond B., et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 169 1-2 (Oct 31 1999) 13-21
21. Cox D.R. Regression models and life tables. J R Stat Soc B 34 (1972) 187-220
22. Brooks B.R. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci 124 (Jul 1994) 96-107 Suppl
23. Ringel S.P., Murphy J.R., Alderson M.K., Bryan W., England J.D., Miller R.G., et al. The natural history of amyotrophic lateral sclerosis. Neurology 43 7 (Jul 1993) 1316-1322
24. Lee J.R., Annegers J.F., and Appel S.H. Prognosis of amyotrophic lateral sclerosis and the effect of referral selection. J Neurol Sci 132 2 (Oct 1995) 207-215
25. Traynor B.J., Zhang H., Shefner J.M., Schoenfeld D., and Cudkowicz M.E. Functional outcome measures as clinical trial endpoints in ALS. Neurology 63 10 (Nov 23 2004) 1933-1935
26. Al-Chalabi A., Scheffler M.D., Smith B.N., Parton M.J., Cudkowicz M.E., Andersen P.M., et al. Ciliary neurotrophic factor genotype does not influence clinical phenotype in amyotrophic lateral sclerosis. Ann Neurol 54 1 (Jul 2003) 130-134
27. Turner M.R., Parton M.J., Shaw C.E., Leigh P.N., and Al-Chalabi A. Prolonged survival in motor neuron disease: a descriptive study of the King's database 1990-2002. J Neurol Neurosurg Psychiatry 74 7 (Jul 2003) 995-997
28. Christensen P.B., Hojer-Pedersen E., and Jensen N.B. Survival of patients with amyotrophic lateral sclerosis in 2 Danish counties. Neurology 40 4 (Apr 1990) 600-604
29. Armon C., and Moses D. Linear estimates of rates of disease progression as predictors of survival in patients with ALS entering clinical trials. J Neurol Sci 160 Suppl 1 (Oct 1998) S37-S41
30. Lyall R.A., Donaldson N., Polkey M.I., Leigh P.N., and Moxham J. Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain 124 Pt 10 (Oct 2001) 2000-2013
31. Mustfa N., and Moxham J. Respiratory muscle assessment in motor neurone disease. Qjm 94 9 (Sep 2001) 497-502
32. Schmidt E.P., Drachman D.B., Wiener C.M., Clawson L., Kimball R., and Lechtzin N. Pulmonary predictors of survival in amyotrophic lateral sclerosis: use in clinical trial design. Muscle Nerve 33 1 (Jan 2006) 127-132
33. Bensimon G., Lacomblez L., and Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 330 9 (Mar 3 1994) 585-591
34. Armon C., Graves M.C., Moses D., Forte D.K., Sepulveda L., Darby S.M., et al. Linear estimates of disease progression predict survival in patients with amyotrophic lateral sclerosis. Muscle Nerve 23 6 (Jun 2000) 874-882
35. Gordon P.H., and Cheung Y.K. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 67 7 (Oct 10 2006) 1314-1315 author reply-5
36. Andersen P.M., Borasio G.D., Dengler R., Hardiman O., Kollewe K., Leigh P.N., et al. EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. Eur J Neurol 12 12 (Dec 2005) 921-938